Melanotan I

Overview

What is Melanotan I?

Melanotan I (afamelanotide) is a synthetic analog of α-melanocyte stimulating hormone that selectively targets MC1 receptors to stimulate melanin production. While an FDA-approved implant version (SCENESSE®) exists for rare medical conditions, research-grade injectable Melanotan I is studied for its photoprotective and tanning effects through regular subcutaneous administration.

Key Benefits

Research-grade injectable Melanotan I provides precise dosing control and rapid onset of tanning effects. Unlike the FDA-approved SCENESSE® implant, injectable form allows flexible dosing and can be administered at home. Produces visible tanning within 1-2 weeks with proper UV exposure.

Mechanism of Action

Subcutaneous injection delivers Melanotan I directly into systemic circulation with 100% bioavailability. 30-minute half-life requires multiple daily injections for sustained MC1R activation and melanin production.

Research Indications

Enhanced Tanning Response

Stimulates melanin production allowing deeper, longer-lasting tan with reduced UV exposure requirements

Photoprotection

Increased melanin density provides natural protection against UV damage and reduces sunburn susceptibility

Even Pigmentation

Promotes uniform melanin distribution reducing patchy tanning and providing consistent skin tone

UV Damage Prevention

Enhanced melanin acts as natural sunscreen reducing photoaging and UV-induced skin damage

Antioxidant Effects

Stimulated eumelanin provides cellular antioxidant protection against free radicals

Reduced Sun Exposure Need

Achieves desired tanning with less UV exposure, minimizing cumulative skin damage

Melanocortin System Research

Tool for studying MC1R receptor function and melanin biosynthesis pathways

Photoprotection Studies

Research model for natural photoprotective mechanisms and UV damage prevention

Cosmetic Applications

Investigation of safe tanning methods and pigmentation enhancement techniques

Research Protocols

Disclaimer

These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Initial Tanning (Light Skin) 0.25mg 2x daily SubQ
Maintenance Tanning 0.5mg 1x daily SubQ
Enhanced Pigmentation 0.5mg 2x daily SubQ
Photoprotection Only 0.25mg 1x daily SubQ

Timing

Multiple daily injections needed due to 30-minute half-life. Best results when combined with minimal UV exposure 2-3 hours after injection for enhanced melanin synthesis.

Peptide Interactions

Both target melanocortin receptors but Melanotan I has better safety profile and selectivity for MC1R. Should not be combined due to overlapping mechanisms and additive effects.
Melanotan I enhances tanning response to UV exposure, allowing deeper pigmentation with less sun exposure. Reduces required UV dose for tanning by approximately 50%.
Natural carotenoid provides additional photoprotection. No known interactions with Melanotan I. Can be used together for enhanced skin protection.
Retinoids increase skin photosensitivity while Melanotan I provides photoprotection. Monitor for skin reactions and adjust UV exposure accordingly.
Antibiotics, diuretics, and other photosensitizing drugs may increase UV sensitivity. Enhanced monitoring recommended when combining with Melanotan I.
Topical self-tanners work through different mechanisms (DHA) and can be used alongside Melanotan I for enhanced cosmetic appearance.

How to Reconstitute

Important

Use BAC water. Light sensitive - store in dark location or wrap vial to protect from light. Refrigerate and use within 30 days.

  • 1
    Allow vial to reach room temperature (15-20 minutes)
  • 2
    Clean vial top with alcohol swab and allow to dry
  • 3
    Calculate required bacteriostatic water volume using the calculator below
  • 4
    Draw calculated volume of bacteriostatic water into syringe
  • 5
    Inject water slowly down the inside wall of the vial (never directly onto powder)
  • 6
    Gently swirl until powder completely dissolves (never shake)
  • 7
    Solution should be clear - discard if cloudy or contains particles
  • 8
    Store reconstituted solution in refrigerator at 2-8°C

Quality Indicators

  • ✓

    Third-party laboratory testing

    Reputable vendors provide HPLC purity testing and amino acid analysis confirming >98% purity

  • ✓

    Proper peptide storage

    Lyophilized powder stable at room temperature during shipping, refrigerate upon arrival

  • ✓

    Clear reconstitution

    Properly reconstituted Melanotan I should be completely clear and colorless without particles

  • ✗

    Premixed solutions

    Avoid pre-mixed liquid Melanotan I as peptides degrade rapidly in solution without proper preservation

  • ✓

    Minimal side effects

    High-quality Melanotan I should cause only mild nausea and flushing, not severe reactions

What to Expect

  • Days 1-3: Possible mild nausea, facial flushing, reduced appetite

  • Days 3-7: Initial skin darkening, increased pigmentation of moles and freckles

  • Week 1-2: Noticeable tanning with minimal UV exposure, enhanced tanning response

  • Week 2-4: Peak tanning effects, maintained pigmentation with reduced injection frequency

Side Effects & Safety

  • Research peptide - not approved for human consumption, sold for research purposes only
  • Start with lower doses to assess individual tolerance and response
  • Monitor moles and skin changes - perform regular self-examinations
  • Use proper sterile injection technique to prevent infections
  • Maintain UV protection despite enhanced tanning - still risk of overexposure
  • Severe nausea, vomiting, or gastrointestinal distress lasting more than 24 hours
  • Rapid or concerning changes in moles, freckles, or existing pigmented lesions
  • Signs of injection site infection: persistent redness, swelling, warmth, or discharge
  • Unusual skin reactions: rashes, hives, or severe itching
  • Any signs of allergic reaction: difficulty breathing, facial swelling, severe dizziness

References

Safety Profile Assessment (2006)

Humans | 147 subjects | Multiple doses | Minimal adverse events

Comprehensive safety evaluation showing excellent tolerability profile with transient nausea and flushing as primary side effects. No serious adverse events reported.

View Study →

MT-I Photoprotection Study (2004)

Humans | 0.08-0.16 mg/kg | 28 days | Enhanced tanning, reduced UV damage

Clinical study demonstrating Melanotan I ability to induce protective tanning with reduced UV exposure requirements. Subjects showed enhanced melanin production and decreased sunburn susceptibility.

View Study →

Tanning Efficacy Comparison (2003)

Humans | vs placebo | UV-free tanning assessment

Study demonstrating Melanotan I ability to produce visible tanning without UV exposure, though enhanced effects observed when combined with minimal UV exposure.

View Study →

Melanocortin Receptor Binding Study (1997)

In vitro | Multiple concentrations | MC1R selectivity analysis

Comprehensive analysis showing Melanotan I 1000-fold higher binding affinity to MC1R compared to natural α-MSH, with minimal binding to other melanocortin receptors.

View Study →

Pharmacokinetics of Injectable MT-I (1997)

Humans | Subcutaneous injection | 30-minute half-life | 100% bioavailability

Pharmacokinetic study establishing subcutaneous bioavailability and rapid clearance profile of injectable Melanotan I, requiring multiple daily administrations for sustained effects.

View Study →